FDA 규제 화합물
이 화합물은 FDA 승인 또는 규제 대상입니다. 유효한 처방 없이 구매하는 것은 연방법 위반일 수 있습니다. 지역 법규를 확인하세요.
Dulaglutide
Trulicity
Dulaglutide is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, marketed under the brand name Trulicity. It consists of a GLP-1 analog covalently linked to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. It is FDA-approved for the treatment of type 2 diabetes mellitus with demonstrated cardiovascular benefit.
작용 메커니즘
GLP-1 receptor agonist fused to a modified IgG4 Fc fragment for extended duration. Weekly dosing improves compliance.
연구 프로토콜
연구 용도만 사용 가능. 의학적 조언은 아닙니다.
Research protocols use 0.75mg weekly, escalating to 1.5mg weekly after 4 weeks. Maximum studied dose is 4.5mg weekly.
연구 노트
Clinical Research Status
Dulaglutide received FDA approval in 2014 for type 2 diabetes and has been studied in the extensive AWARD clinical trial program spanning multiple comparator studies. The REWIND cardiovascular outcomes trial demonstrated a 12% reduction in MACE in a broad population including primary prevention patients. It is not currently approved for weight management as a standalone indication.
Key Published Findings
The AWARD trials showed HbA1c reductions of 0.8-1.6% depending on comparator and population studied. REWIND was notable for enrolling a majority of patients without established cardiovascular disease, demonstrating broader preventive benefit. Weight loss in diabetes trials averaged 1.5-3 kg, modest compared to newer GLP-1 agonists optimized for obesity.
Safety Profile
Gastrointestinal adverse events (nausea, diarrhea, vomiting) are the most common side effects, occurring in 15-25% of patients during titration. The same class-wide MTC boxed warning applies, based on rodent thyroid C-cell tumor findings. Injection site reactions are generally mild, and the pre-filled pen device has high patient satisfaction scores.
Comparison to Related Compounds
Compared to semaglutide, dulaglutide produces less weight loss and slightly less HbA1c reduction but uses a simpler auto-injector device that some patients prefer. Its large molecular size (approximately 63 kDa) prevents oral bioavailability, unlike semaglutide which has an oral formulation. Relative to liraglutide, the weekly dosing of dulaglutide offers significant convenience advantage with comparable efficacy.
Community Observations
Trulicity's pen device is frequently cited as one of the most user-friendly among injectable GLP-1 agonists, requiring no needle handling. Patients transitioning from dulaglutide to semaglutide for greater weight loss often report stronger GI side effects initially. Some endocrinologists continue prescribing dulaglutide for patients who prioritize injection simplicity and have modest weight loss goals.
반감기
~5 days
재조성
Pre-filled pen (no reconstitution)
보관
건조한 상태
Refrigerate 2-8C. Do not freeze.
재조성된 상태
Room temperature up to 14 days if needed.
미국 법적 상태
또는 알려진 이름으로
최신 연구
Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.
Highlighting the latest advancements and considerations for clinicians using GLP-1 receptor agonists and tirzepatide in treating type 2 diabetes and obesity.
Highlighting the safety and potential benefits of GLP-1 receptor agonists in managing type 2 diabetes patients with or at risk for acute pancreatitis.
자주 묻는 질문
Dulaglutide란 무엇인가요?
Dulaglutide is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, marketed under the brand name Trulicity. It consists of a GLP-1 analog covalently linked to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. It is FDA-approved for the treatment of type 2 diabetes mellitus with demonstrated cardiovascular benefit.
Dulaglutide는 어떻게 작용하나요?
GLP-1 receptor agonist fused to a modified IgG4 Fc fragment for extended duration. Weekly dosing improves compliance.
Dulaglutide의 미국 규제 현황은 어떤가요?
FDA-approved (Rx only)
Dulaglutide의 반감기는 얼마인가요?
~5 days
Dulaglutide의 다른 이름은 무엇인가요?
Trulicity
Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.
전체 공지사항 읽기